Alport Syndrome: A Comprehensive Analysis of its Pathogenic Basis, Clinical Manifestations, Diagnostic Approaches, and Integrated Management Strategies
Main Article Content
Abstract
The present article stands as a thorough and holistic exploration of Alport syndrome, a uniquely complex inherited nephropathological entity involving a myriad of etiological, clinical and therapeutic aspects. Through a meticulous synthesis of the current scientific literature, this review encompasses a comprehensive appreciation of the underlying genetic basis of the disease, characterized by an aberrant expression of type IV collagen proteins in the glomerular basement membrane, which precipitates a cascade of pathophysiological events with multisystemic implications.
The clinical manifestations of Alport syndrome, although classically centered on progressive nephropathy with hematuria and proteinuria, have evolved to include a plethora of variant phenotypes affecting not only the renal, but also the auditory and ocular systems. This phenotypic expansion demands a meticulous differential diagnostic approach, supported by advanced imaging techniques, auditory function studies, and precise genetic analysis, for the sake of early and accurate identification of the condition.
Early and accurate diagnosis of Alport syndrome is an essential pillar for effective clinical management and the application of appropriate therapeutic strategies. In this context, the available therapeutic approaches are reviewed in detail, ranging from conservative renal disease therapy to innovative pharmacological interventions and, in some cases, renal transplantation. The importance of multidisciplinary care and genetic counseling for affected families is also discussed, in line with the comprehensive approach to this multisystemic and hereditary condition.
In summary, this comprehensive review of Alport syndrome amalgamates a deep appreciation of its genetic, pathophysiological and clinical aspects, while promoting the imperative need for a collaborative, multidisciplinary approach to its proper management. Through the integration of advanced medical research and clinical experience, we aspire not only to a more acute understanding of this entity, but also to a substantial improvement in the quality of life of the patients who suffer from it.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. J. Savige, M. Gregory, O. Gross, C. Kashtan, J. Ding, and F. Flinter, Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol, vol. 24, no. 3, pp. 364¿375, Feb. 2013, doi: 10.1681/ASN.2012020148.
II. C. E. Kashtan et al, Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol, vol. 28, no. 1, pp. 511, Jan. 2013, doi: 10.1007/s00467-012-2138-4.
III. C. E. Kashtan et al, Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group.,¿ Kidney Int, vol. 93, no. 5, pp. 1045¿1051, May 2018, doi: 10.1016/j.kint.2017.12.018.
IV. J. P. Jais et al., X-linked Alport Syndrome: Natural History in 195 Families and Genotype-Phenotype Correlations in Males,¿ 2000.
V. J. Savige et al, Alport Syndrome in Women and Girls, Clin J Am Soc Nephrol, vol. 11, no. 9, pp. 1713-1720, Sep. 2016, doi: 10.2215/CJN.00580116.
VI. M. N. Rheault, ¿Women and Alport syndrome, Pediatric Nephrology, vol. 27, no. 1. pp. 4146, Jan. 2012. doi: 10.1007/s00467-011-1836-7.
VII. J. Savige et al, X-linked and autosomal recessive alport syndrome: Pathogenic variant features and further genotype-phenotype correlations PLoS One, vol. 11, no. 9, Sep. 2016, doi: 10.1371/journal.pone.0161802.
VIII. J. Gibson et al, Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome, J Am Soc Nephrol, vol. 32, no. 9, pp. 2273¿2290, Sep. 2021, doi: 10.1681/ASN.2020071065.
IX. C. P. Thomas et al, Screening of Living Kidney Donors for Genetic Diseases Using a Comprehensive Genetic Testing Strategy, Am J Transplant, vol. 17, no. 2, pp. 401410, Feb. 2017, doi: 10.1111/ajt.13970.
X. M. N. Rheault and C. E. Kashtan, Alport syndrome and thin basement membrane nephropathy,¿ Pediatric Kidney Disease: Second Edition, pp. 499¿514, 2017, doi: 10.1007/978-3-662-52972-0_18.
XI. C. Pescucci et al., Autosomal-dominant Alport syndrome: Natural history of a disease due to COL4A3 or COL4A4 gene,¿ in Kidney international, May 2004, vol. 65, no. 5, pp. 1598-1603. doi: 10.1111/j.1523-1755.2004.00560.x.
XII. N. Kamiyoshi et al, Genetic, Clinical, and Pathologic Backgrounds of Patients with Autosomal Dominant Alport Syndrome,¿ Clin J Am Soc Nephrol, vol. 11, no. 8, pp. 1441-1449, Aug. 2016, doi: 10.2215/CJN.01000116.
XIII. M. Furlano et al, Clinical and Genetic Features of Autosomal Dominant Alport Syndrome: A Cohort Study, American Journal of Kidney Diseases, vol. 78, no. 4, pp. 560-570.e1, Oct. 2021, doi: 10.1053/J.AJKD.2021.02.326.
XIV. C. Fallerini et al, Alport syndrome: impact of digenic inheritance in patients management.,¿ Clin Genet, vol. 92, no. 1, pp. 34¿44, Jul. 2017, doi: 10.1111/cge.12919.
XV. C. Deltas, Digenic inheritance and genetic modifiers, Clin Genet, vol. 93, no. 3, pp. 429¿438, 2018, doi: 10.1111/cge.13150.
XVI. S. Daga et al, Non-collagen genes role in digenic Alport syndrome, BMC Nephrol, vol. 20, no. 1, p. 70, Feb. 2019, doi: 10.1186/s12882-019-1258-5.